Recent

% | $
Quotes you view appear here for quick access.

Endocyte, Inc. (ECYT) Message Board

cash2go 156 posts  |  Last Activity: Apr 16, 2015 8:06 PM Member since: Feb 8, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • cash2go cash2go Apr 16, 2015 8:06 PM Flag

    Big Pharma and Wall Street hate nothing more than a renegade doing compassionate use while a drug trial is going on. The boyz also hat to see a CEO hinting at the positive trial results she sees insinuated in the company reports she is seeing daily. Thats the kind of info Wall Street, Big Pharma and inside doctors play with "legally" to make billions off their customers.

    Woodworth is one of the billion dollar boys that seems to have broken the truce and decided to trade off the compassionate use data. Wouldn't you like to be a fly on the wall as they were discussing what they had found out as they were snooping around the patients and doctors involved with the compassionate use data.

    GLTA, looking forward to Adam F exposing the cancer patients and doctors for the data they cooked up in the latest new release.

  • Reply to

    How much time does "FAST TRACKED" save?

    by abeta4238 Apr 16, 2015 4:56 PM
    cash2go cash2go Apr 16, 2015 7:30 PM Flag

    Remember that would be 3 or 6 months off of 8 year trials. Fast Track status is not as big a deal as Wall Street makes it out to be, the price bumps are usually very short lived. Fast Track is also not that difficult to get and somewhat routine.
    Accelerated Approval and BreakThrough Status are the money makers.

  • Would Northwest Biotherapeutics be one of the best known and liked autologous immunotherapy cancer therapy companies on Wall Street. An early leader in autologous immunotherapy before it became the buzz word for making money on Wall Street he's had nothing but bad things to say about the company?

    Just a reminder to all as the stock price moves up and Northwest has potential for some exciting news Adam must be hard at work with a nasty article.

    Autologous immunotherapy, Adam missed the boat but has enjoyed the hits on his site (hits = money) when he goes after Northwest.

  • April 2, 2015
    Woodford will purchase $40 million of the Company's common stock

    March 27, 2015
    NW BIO REPORTS PROMISING SURVIVAL DATA IN 51 GBM PATIENTS TREATED WITH DCVAX®-L

    * Woodford's high paid analysts/scientist must have seen something they like. Not sure if these boys have enough cash to take this pipeline private.

  • cash2go cash2go Apr 16, 2015 12:49 PM Flag

    Juno and the rest of the CAR T treatments are looking at $500,000 per tx. IF NWBO's offers an alternative it will be first line for all qualified patients. Northwest really needs someone that can play the game better with Wall Street. wink, wink.

    Congrats to the compassionate cases that got months to years of a better life with their loved ones and to do some of the things they never got to do. Too bad FDA hates compassionate use and will punish NWBO when reviewing their trials. And, YES they will.

  • Reply to

    Exhibitor Spotlight Presentations at the AACR

    by itrizia Apr 15, 2015 11:49 AM
    cash2go cash2go Apr 15, 2015 2:17 PM Flag

    Apr 20, 2015

    3:00PM - 4:00PM
    Browse Details Exhibitor Spotlight Presentation.Northwest Biotherapeutics: Clinical Development of Dendritic Cell-Based Therapies for Both Resectable and Unresectable Tumors
    Exhibitor Spotlight Theater B, Halls B-E

    As it hates to do it the medical research community is giving NWBO a little respect. Hope to hear some good stories about the results seen in some of the compasionate cases.

    55 GBM patients with DCVax-L on a compassionate basis in an “Information Arm” outside of the Phase III trial. and if NWBO is seeing positive results it would be hard to hide. NOTE:
    April 6, 2015
    High-profile U.K. investor Neil Woodford is putting more chips on the controversial Northwest Biotherapeutics ($NWBO), betting another $40 million on the company as it works through Phase III with a cancer vaccine.

    The Medical Professionals and analysts are going to hate it if we are about to hear good news on April 20. So many seem to hate this stock.

    Could be a very good Monday for GBM patients and for shareholders

    GLTA.

  • Reply to

    CLSN press release rehash of old news

    by dtrader12 Apr 15, 2015 10:40 AM
    cash2go cash2go Apr 15, 2015 12:02 PM Flag

    It's a day trader thing. Watch that $3 level, all traders start exiting at once. EOD also could hurt.

    On the other hand. It's great news for the resistant chest wall patient, a very very small market.

  • Reply to

    Sold 15k shares @ $3.45 to get my money back

    by dailyblumpkins Feb 24, 2015 9:53 AM
    cash2go cash2go Apr 15, 2015 11:33 AM Flag

    Traders having fun today. All exit at EOD may give you the stock back at $250 today. Tiny study and results were expected for chest wall. If it threatens to lose $3 traders should flee ASAP.

    GLTA.

  • Company is raising cash when it hurts, sub $1 share price. Autologous T Cell therapy (CAR T) showing very promising results in cancer tx. Problem is the $500,0000/yr cost to patient. Anyone know if Opexa has a cost effective production answer for it's autologous T cell therapy?

  • Reply to

    Draper fired in 2007 & Rose becomes CEO in 2007

    by cash2go Apr 10, 2015 2:29 AM
    cash2go cash2go Apr 14, 2015 2:43 AM Flag

    Great points, thanks for posting.

    Intentionality clearly plays a crucial role in white collar criminal prosecutions. In fact, it is usually a key element of the charged white collar offenses

    Lorandos & Joshi on litigation overview is a good read on what is possible. Funny how the bashers (who are they really) coming to this board find no fault in one the worst boards on Wall Street. It has cost "real" small investors a fortune.

    I'm 99% sure we will never see ciminal prosecutions in this case, no matter how obvious.

    GLTA small investors.

  • Reply to

    Draper fired in 2007 & Rose becomes CEO in 2007

    by cash2go Apr 10, 2015 2:29 AM
    cash2go cash2go Apr 13, 2015 5:42 PM Flag

    Those dates are starting to roll in:

    A hearing on the request for an investigation is set for April 22. Responses to the creditors' filing are due by April 15.

    Criminal investestigations are now possible? Can't wait for those books to be open and all the truths to be exposed.

  • Reply to

    Draper fired in 2007 & Rose becomes CEO in 2007

    by cash2go Apr 10, 2015 2:29 AM
    cash2go cash2go Apr 13, 2015 5:37 PM Flag

    Lawyers for the creditors say they are asking for the investigation because a Delaware court ruled Siga "acted in bad faith," and the company hasn't taken action against any of its executives or board members.
    "In these circumstances, it is the committee's duty to investigate whether claims exist relating to Siga's conduct in relation to its liability to PharmAthene ," the creditors said.
    The investigation into the stock sales, if granted, would be related to Siga's claim to be a small-business company when applying for a contract to sell Tecovirimat, its smallpox vaccine, in 2011. The contract, which the company said in a news release at the time could have been worth up to $2.8 billion, was rescinded because Siga had too many employees to be considered a small business. The contract the company ended up with was much smaller.
    Creditors say several board members including Chairman and Chief Executive Eric Rose , sold shares of Siga in between the time of the announcement of the possible $2.8 billion contract and the subsequent disclosure of the actual lower contract amount.
    The stock trades, creditors said in their filing, "compel an investigation by the committee, including determining whether Siga's officers and directors properly discharged their fiduciary duties to SIGA."
    A hearing on the request for an investigation is set for April 22. Responses to the creditors' filing are due by April 15.

  • Reply to

    How will Delaware Supreme Court rule on appeal?

    by cash2go Apr 10, 2015 10:10 PM
    cash2go cash2go Apr 13, 2015 5:29 PM Flag

    $113 million plus interest. Considered very low with the primate trial and human safety trial behind them. Remember the $100 million bonus just for getting the two animal FDA approval for bioterror weapons? Zero chance Pharmathene nor Siga would have settled for anything close to $113 million in September 2006. $180 was my nightmare low end, before interest, and Judge Parsons probably expected the Supreme Court to send this case back to him with more explicit instructions.

    Supreme Court did clarify a lot when it told Siga to pay millions in Pharmathene's legal fees. Also agree that Siga is risking paying more than $190 million as the Supreme Court's last Opinion said a lot in clarifying the way PIP used bad faith for litigation.

    ill intent, shall not go easily into the night.

  • cash2go cash2go Apr 13, 2015 12:07 PM Flag

    Wall Street hates litigation. Especially the litigation Perelman and the Siga team can afford, a Chapter 11 Siga I remind you. What I don't know has kept this a small position for me, out of respect.
    I've read plenty of opinions from Delaware Supreme Court and Jusdge Parsons. They don't seem impressed by the Siga team. Hopefully the little guy like me sneaks in and wins a big one (in less than 6 months).
    Noticed over time there is a huge seller in PIP in the $1.75 range. If this appeal goes to Supreme Court I hope to load up at a lower price, panic selling. Feels like a lot of lurkers trying to buy in $1.50's, my wild guess.

    If it gets over $1.80 on volume and holds a few days will add there.

    GLTA small investors

  • Reply to

    CAR T Bubble?

    by cash2go Apr 7, 2015 11:06 PM
    cash2go cash2go Apr 13, 2015 11:53 AM Flag

    Expecting reasonable entry prices at end of summer, thats just how biotech often goes. Could be as late as October. More will be known and some bubbles will be popped by reality? Cellectis is very early and the CAR T race with a lot to prove.
    They did a great IPO and pulled in lots of bucks needed for this long range investment.

    GLTA

  • Apr 13, 2015, 8:51 AM

    a one-time payment of $5.8 million related to the reconciliation between the actual and the provisional rates on the performance of the SparVax® contract for the years 2008 through 2013 for actual costs incurred

    * the war chest grows

  • Reply to

    How will Delaware Supreme Court rule on appeal?

    by cash2go Apr 10, 2015 10:10 PM
    cash2go cash2go Apr 12, 2015 2:07 AM Flag

    Delaware Supreme Court:
    On remand, the Vice
    Chancellor shall redetermine his damage award in light of this opinion and is free to reevaluate the helpfulness of expert testimony.

    * I think that is what Judge Parsons did when awarding the low end of expectation damages. Appeal?

  • Reply to

    The Big Picture on Portola

    by manoflamatzah Mar 5, 2015 1:39 AM
    cash2go cash2go Apr 10, 2015 11:48 PM Flag

    Agree, first to market is a big advantage. Doctors will no doubt feel the pressure to go with the anticoagulant that has a an antidote. Seen the late night lawsuit commercials mentioning these new anticoagulants? You can probably google them up if you haven't seen them.

    Over the years Pradaxa will lose the antidote advantage and market share.

  • A hint from previous appeal:

    Court May Award Attorney Fees in Certain Cases

    Bad Faith: If a party acted in bad faith, the court can order that party to pay the other party's attorney fees. For example, if a party defies a court order and is found in contempt of court, the judge could order that party to pay the other party's attorney fees. Also, if a party commits a fraud on the court, the judge might order that party to pay the attorney fees of the other party.

  • Law360, New York (April 09, 2015, 7:07 PM ET) -- Siga Technologies Inc. creditors asked a New York bankruptcy court Wednesday to greenlight an investigation into Siga executives who allegedly dumped stock after an adverse contract decision and drove the embattled defense contractor and smallpox-drug maker to the brink of insolvency with "bad faith" conduct in a merger and licensing deal.

    The statutory creditors’ committee, which represents the interests of Siga's general unsecured claimholders, asked U.S. Bankruptcy Judge Sean H. Lane to open a probe into directors, officers, executives and controlling shareholders at Siga, according to...

    *********************************************************************************

    Bad Faith and ill will may soon be turning on itself. Once an investigation begins turning up cockroaches...

ECYT
6.17-0.08(-1.28%)Apr 17 4:00 PMEDT